Table 1.9a

Immunosuppression Use by Organ in 2005 and 2006

  Organ
Kidney PTA PAK KP Liver Intestine Heart Lung Heart-Lung
Transplants (2006)   17,093 169 293 924 6,649 174 2,192 1,406 31
Tx With Immunosuppression Info at Discharge   16,505 165 281 879 6,380 168 2,102 1,366 30
Induction Drug Reported 78.6% 80.0% 78.3% 82.7% 22.7% 58.3% 54.7% 57.2% 60.0%
Induction Drugs Atgam/NRATG/NRATS 0.6% 0.6% 0.0% 0.7% 0.3% 0.6% 4.7% 5.9% 3.3%
OKT3 1.1% 5.5% 0.7% 0.8% 2.7% 14.3% 3.1% 1.3% 0.0%
Thymoglobulin 42.3% 42.4% 56.2% 62.0% 8.9% 17.9% 18.0% 4.0% 6.7%
Zenapax 11.2% 10.9% 2.5% 5.0% 5.7% 17.3% 14.6% 15.7% 16.7%
Simulect 17.8% 2.4% 6.8% 5.2% 6.5% 3.0% 14.9% 24.4% 10.0%
Campath 10.0% 24.2% 13.5% 11.4% 1.4% 21.4% 1.7% 7.2% 23.3%
Tx With Immunosuppression Info and Functioning Graft at Discharge   16,257 150 248 867 6,043 148 1,982 1,294 24
Maintenance at Discharge Corticosteroids Use   67.7% 51.3% 63.3% 66.8% 78.4% 73.6% 92.2% 97.4% 100.0%
Steroids 67.7% 51.3% 63.3% 66.8% 78.4% 73.6% 92.2% 97.4% 100.0%
Calcineurin Inhibitor Use   94.4% 98.0% 97.2% 98.6% 98.0% 98.0% 97.5% 98.8% 104.2%
Cyclosporine 12.0% 2.0% 5.6% 6.2% 6.7% 0.0% 37.9% 16.1% 29.2%
Tacrolimus 82.4% 96.0% 91.5% 92.4% 91.2% 98.0% 59.6% 82.8% 75.0%
Antimetabolite Use   88.7% 54.7% 84.3% 85.0% 69.1% 18.9% 91.4% 92.8% 91.7%
Mycophenolate Mofetil 76.1% 50.7% 75.0% 72.4% 65.0% 18.2% 83.3% 51.9% 70.8%
Mycophenolate Sodium 11.7% 4.0% 8.9% 11.4% 3.7% 0.0% 3.4% 2.5% 0.0%
Azathioprine 0.9% 0.0% 0.4% 1.2% 0.4% 0.7% 4.7% 38.5% 20.8%
Leflunomide 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
mTOR Inhibitor Use   8.8% 26.0% 16.1% 16.3% 3.8% 10.1% 6.2% 1.7% 0.0%
Sirolimus 8.3% 26.0% 16.1% 16.3% 3.7% 10.1% 3.6% 1.7% 0.0%
Everolimus 0.5% 0.0% 0.0% 0.0% 0.0% 0.0% 2.5% 0.0% 0.0%
Transplants (2005)   16,481 198 343 903 6,441 176 2,125 1,407 35
Tx With Maintenance Use at 1yr PostTx   14,491 147 256 803 4,997 129 1,782 1,113 25
Maintenance at 1yr PostTx Corticosteroids Use   69.3% 44.9% 67.6% 69.1% 40.6% 55.0% 69.2% 99.1% 92.0%
Steroids 69.3% 44.9% 67.6% 69.1% 40.6% 55.0% 69.2% 99.1% 92.0%
Calcineurin Inhibitor Use   91.4% 96.6% 96.1% 95.6% 92.3% 97.7% 96.4% 97.3% 100.0%
Cyclosporine 13.9% 2.0% 5.9% 6.4% 8.5% 1.6% 33.8% 14.2% 12.0%
Tacrolimus 77.5% 94.6% 90.2% 89.3% 83.8% 96.1% 62.6% 83.1% 88.0%
Antimetabolite Use   85.7% 57.1% 85.2% 78.3% 44.8% 10.1% 87.9% 83.8% 80.0%
Mycophenolate Mofetil 73.9% 44.2% 75.0% 56.7% 41.1% 7.0% 78.8% 51.8% 52.0%
Mycophenolate Sodium 10.1% 10.2% 8.2% 20.9% 3.1% 0.0% 4.0% 4.9% 4.0%
Azathioprine 1.3% 2.7% 2.0% 0.5% 0.7% 3.1% 5.0% 27.0% 24.0%
Leflunomide 0.5% 0.0% 0.0% 0.2% 0.0% 0.0% 0.1% 0.1% 0.0%
mTOR Inhibitor Use   14.1% 19.7% 17.2% 19.6% 11.2% 16.3% 10.0% 7.5% 8.0%
Sirolimus 13.8% 19.7% 17.2% 19.6% 11.2% 16.3% 9.7% 7.5% 8.0%
Everolimus 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.